Session: (1734–1775) RA – Etiology and Pathogenesis Poster
1775: The Peptidyl Arginine Deiminase Inhibitor BB-CLA Decreases the Inflammatory and Fibrotic Responses in Macrophages and Rheumatoid Arthritis Synovial Fibroblasts Exposed to Fibrinogen Modified with Malondialdehyde-Acetaldehyde Adduct and Citrulline
University of Nebraska Medical Center Omaha, NE, United States
Disclosure information not submitted.
Jack Mordeson1, Nozima Aripova1, Michael Duryee1, James O'Dell1, Bryant England1, Daniel Anderson1, Ted R Mikuls2 and Geoffrey Thiele1, 1University of Nebraska Medical Center, Omaha, NE, 2Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Peptide citrullination and adduction with malondialdehyde-acetaldehyde adduct (MAA) are post-translational modifications involved in the pathogenesis of rheumatoid arthritis (RA). Anti-cyclic-citrullinated peptide antibodies are >90% specific for the diagnosis of RA. Our laboratory has shown co-localization of MAA with citrullinated proteins in RA synovial fluid, elevated anti-MAA antibodies in RA patients, and pro-inflammatory and pro-fibrotic responses to MAA-modified antigens by macrophages in vitro. In addition, macrophages demonstrate increased expression of peptidyl arginine deiminase-2 (PAD2), an isozyme of PAD, in response to these MAA-adducted and citrullinated proteins. PAD catalyzes protein citrullination and may mediate the immunogenic transformation of synovial proteins and subsequent auto-antibody formation in RA. Here, we determine whether inhibition of PAD effects inflammatory and fibrotic markers in macrophages and RA human fibroblast-like synoviocytes (HFLS-RA) in response to stimulation with MAA and citrulline (CIT)-modified fibrinogen (FIB).
Methods: U-937 monocyte cell line was differentiated into activated macrophages by exposure to LPS, and subsequently stimulated with; unmodified FIB, FIB-CIT, or FIB-MAA-CIT in the presence (treatment group) and absence (control group) of BB-CLA (a general PAD inhibitor; PADi) for 48 hours. Supernatants collected from the media were assessed by ELISA for the pro-inflammatory cytokines; interleukin-1b (IL-1b), interleukin-6 (IL-6), interleukin-8 (IL-8), and monocyte chemoattractant protein-1 (MCP-1). HFLS from RA patients were stimulated with treatment and control supernatants from the antigen-stimulated macrophage cultures and assessed via immunofluorescent staining for the fibrotic markers vimentin and type II collagen.
Results: As previously reported, the modification of FIB with CIT and or MAA-CIT statistically increases the concentrations of the pro-inflammatory cytokines measured (Figure 1 A-D, Control). The effect of PAD inhibition on the inflammatory cytokine levels was a decrease in the secretion by stimulated macrophages of these cytokines (Figure 1 A-D, +BB-CLA) back to almost baseline levels. Examination of the HFLS cells stimulated with supernatants from macrophages activated with FIB-CIT or FIB-MAA-CIT showed an increase in both vimentin and Type II Collagen production that was significantly elevated when compared to FIB supernatant stimulation (Figure 2 A-C).
Conclusion: This study provides insight into the degree to which inflammatory and fibrotic responses from macrophages and HFLS to CIT and MAA-CIT modified fibrinogen may be PAD-mediated. Therefore, these observations strongly suggest that CIT and MAA-CIT modification of proteins play a role in the inflammatory and fibrotic responses observed in cells associated with RA development and/or progression. Additionally, they suggest that PAD inhibition is an obvious target for therapeutic intervention.
Figure 1. Inflammatory cytokines from stimulated U-937 cells. U-937 cells were stimulated with native and modified fibrinogen for 48 hours in the presence and absence of BB-CLA. IL-1β (A), IL-6 (B), IL-8 (C), and MCP-1 (D) levels were measured via ELISA. ****p<0.001.
Figure 2. Fibrotic markers from stimulated HFLS-RA cells. U-937 supernatants were utilized for stimulation of HFLS-RA cells. Images were recorded following immunofluorescent staining with anti-vimentin and anti-type II collagen antibodies. ****p<0.001, #p<0.05.
J. Mordeson: None; N. Aripova: None; M. Duryee: None; J. O'Dell: None; B. England: Boehringer-Ingelheim, 2, 5; D. Anderson: None; T. Mikuls: Elsevier, 9, Horizon Therapeutics, 2, 5, Pfizer, 2, Sanofi, 2, UCB Pharma, 2, Wolters Kluwer Health (UpToDate), 9; G. Thiele: None.
.jpg)
.jpg)
